Doxercalciferol (BioDeep_00000006684)
代谢物信息卡片
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
化学式: C28H44O2 (412.3341)
中文名称: 度骨化醇
谱图信息:
最多检出来源 Mus musculus(plant) 5.97%
分子结构信息
SMILES: C1/C(=C/C=C2\CCC[C@]3(C)[C@@]([H])([C@@]([H])(/C=C/[C@@H](C)C(C)C)C)CC[C@@]\23[H])/C(=C)[C@@H](O)C[C@@H]1O
InChI: InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
描述信息
H - Systemic hormonal preparations, excl. sex hormones and insulins > H05 - Calcium homeostasis > H05B - Anti-parathyroid agents
D018977 - Micronutrients > D014815 - Vitamins > D004872 - Ergocalciferols
D050071 - Bone Density Conservation Agents
同义名列表
9 个代谢物同义名
Doxercalciferol; (5Z,7E,22E)-(3S,5R,24S)-9,10-seco-5,7,10(19),22-ergostatetraen-3,24-diol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; (5Z,7E,22E)-(1S,3R)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol; 1alpha-hydroxyergocalciferol; 1alpha-hydroxyvitamin D2; trans-Doxercalciferol; Doxercalciferol
数据库引用编号
19 个数据库交叉引用编号
- ChEBI: CHEBI:4712
- KEGG: C08211
- KEGGdrug: D82103
- KEGGdrug: D01009
- PubChem: 5281107
- PubChem: 24779618
- PubChem: 4479094
- Metlin: METLIN41941
- Metlin: METLIN41905
- DrugBank: DB06410
- ChEMBL: CHEMBL1200810
- LipidMAPS: LMST03010069
- CAS: 54573-75-0
- PMhub: MS000019763
- PubChem: 10410
- LipidMAPS: LMST03010028
- PDB-CCD: V2H
- NIKKAJI: J527.612H
- KNApSAcK: 4712
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Jian Li, Nan Li, Shuangtong Yan, Minyan Liu, Banruo Sun, Yanhui Lu, Yinghong Shao. Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
2020 Aug; 128(8):540-547. doi:
10.1055/a-0754-1956. [PMID: 30380573] - Ravi I Thadhani, Sophia Rosen, Norma J Ofsthun, Len A Usvyat, Lorien S Dalrymple, Franklin W Maddux, Jeffrey L Hymes. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN.
2020 03; 15(3):384-391. doi:
10.2215/cjn.07960719. [PMID: 32111702] - Qunfeng Wu, Xuening Wang, Kien Pham, Aesis Luna, George P Studzinski, Chen Liu. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.
The Journal of steroid biochemistry and molecular biology.
2020 03; 197(?):105524. doi:
10.1016/j.jsbmb.2019.105524. [PMID: 31704246] - X Wang, M Nachliely, J S Harrison, M Danilenko, G P Studzinski. Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen.
The Journal of steroid biochemistry and molecular biology.
2019 03; 187(?):166-173. doi:
10.1016/j.jsbmb.2018.11.015. [PMID: 30508644] - Ladan Zand, Rajiv Kumar. The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.
Endocrinology and metabolism clinics of North America.
2017 12; 46(4):983-1007. doi:
10.1016/j.ecl.2017.07.008. [PMID: 29080646] - Xuening Wang, Jonathan S Harrison, George P Studzinski. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
The Journal of steroid biochemistry and molecular biology.
2016 11; 164(?):72-78. doi:
10.1016/j.jsbmb.2015.08.023. [PMID: 26319201] - Jonathan S Harrison, Xuening Wang, George P Studzinski. The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.
Oncotarget.
2016 Jun; 7(24):36447-36460. doi:
10.18632/oncotarget.8998. [PMID: 27144333] - Renata C Pereira, Harald Jüppner, Barbara Gales, Isidro B Salusky, Katherine Wesseling-Perry. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients.
PloS one.
2015; 10(3):e0120856. doi:
10.1371/journal.pone.0120856. [PMID: 25774916] - T Christopher Bond, Steve Wilson, John Moran, Mahesh Krishnan. Mortality rates do not differ among patients prescribed various vitamin D agents.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
2015 Jan; 35(1):62-9. doi:
10.3747/pdi.2012.00324. [PMID: 24584595] - Jongha Park, Connie M Rhee, Wei Ling Lau, Kamyar Kalantar-Zadeh. Clinical uses of 1-alpha-hydroxy-ergocalciferol.
Current vascular pharmacology.
2014 Mar; 12(2):306-12. doi:
10.2174/15701611113119990025. [PMID: 23713877] - Valentin David, Bing Dai, Aline Martin, Jinsong Huang, Xiaobin Han, L Darryl Quarles. Calcium regulates FGF-23 expression in bone.
Endocrinology.
2013 Dec; 154(12):4469-82. doi:
10.1210/en.2013-1627. [PMID: 24140714] - P C Dheerendra, V Sakhuja, H S Kohli, V Jha. Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4.
Indian journal of nephrology.
2013 Jul; 23(4):271-5. doi:
10.4103/0971-4065.114492. [PMID: 23960343] - Jason Gee, Howard Bailey, Kyungmann Kim, Jill Kolesar, Tom Havighurst, Kendra D Tutsch, William See, Michael B Cohen, Nick Street, Leon Levan, David Jarrard, George Wilding. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
The Prostate.
2013 Jun; 73(9):970-8. doi:
10.1002/pros.22644. [PMID: 23335089] - Jyoti Duggal, Jonathan S Harrison, George P Studzinski, Xuening Wang. Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells.
MicroRNA (Shariqah, United Arab Emirates).
2012; 1(1):26-33. doi:
10.2174/2211536611201010026. [PMID: 25048087] - K Shashi Kant, Alejandro R Gonzalez, Srinivas Hariachar, Marializa Bernardo, Ajay Duggal, Sara Engstrand, John Hunter, Melissa Plone, Joachim Hertel. Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
2012 Jan; 22(1):34-40.e2. doi:
10.1053/j.jrn.2011.02.004. [PMID: 21652220] - Jun H Choi, Qingen Ke, Soochan Bae, Ji Yoo Lee, Yu Jin Kim, Ui Kyoung Kim, Cynthia Arbeeny, Ravi Thadhani, Peter M Kang. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.
Journal of cardiac failure.
2011 Dec; 17(12):1051-8. doi:
10.1016/j.cardfail.2011.08.006. [PMID: 22123370] - Edwin C Y Chow, Myrte Sondervan, Cheng Jin, Geny M M Groothuis, K Sandy Pang. Comparative effects of doxercalciferol (1α-hydroxyvitamin D₂) versus calcitriol (1α,25-dihydroxyvitamin D₃) on the expression of transporters and enzymes in the rat in vivo.
Journal of pharmaceutical sciences.
2011 Apr; 100(4):1594-604. doi:
10.1002/jps.22366. [PMID: 20967888] - Xiaoxin X Wang, Tao Jiang, Yan Shen, Hannah Santamaria, Nathaniel Solis, Cynthia Arbeeny, Moshe Levi. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.
American journal of physiology. Renal physiology.
2011 Mar; 300(3):F801-10. doi:
10.1152/ajprenal.00338.2010. [PMID: 21209008] - Mahesh Krishnan, Patricia McCarley. Comparative effectiveness of active oral vitamin D agents in patients on peritoneal dialysis.
Nephrology news & issues.
2011 Jan; 25(1):27-30. doi:
NULL. [PMID: 21291054] - René St-Arnaud, Alice Arabian, Omar Akhouayri, Joyce C Knutson, Stephen A Strugnell. Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia.
Nephron. Experimental nephrology.
2011; 119(3):e67-74. doi:
10.1159/000329663. [PMID: 21849802] - Katherine Wesseling-Perry, Renata C Pereira, Shobha Sahney, Barbara Gales, He-Jing Wang, Robert Elashoff, Harald Jüppner, Isidro B Salusky. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Kidney international.
2011 Jan; 79(1):112-9. doi:
10.1038/ki.2010.352. [PMID: 20861820] - Kamyar Kalantar-Zadeh, Anuja Shah, Uyen Duong, Rulin C Hechter, Ramanath Dukkipati, Csaba P Kovesdy. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kidney international. Supplement.
2010 Aug; ?(117):S10-21. doi:
10.1038/ki.2010.189. [PMID: 20671739] - Juan Kong, Gene H Kim, Minjie Wei, Tao Sun, George Li, Shu Q Liu, Xinmin Li, Ishir Bhan, Qun Zhao, Ravi Thadhani, Yan Chun Li. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.
The American journal of pathology.
2010 Aug; 177(2):622-31. doi:
10.2353/ajpath.2010.091292. [PMID: 20616348] - Neal Mittman, Brinda Desiraju, Kevin B Meyer, Jyoti Chattopadhyay, Morrell M Avram. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
Kidney international. Supplement.
2010 Aug; ?(117):S33-6. doi:
10.1038/ki.2010.191. [PMID: 20671742] - Sharon M Moe, Akber Saifullah, Robert E LaClair, Sohail A Usman, Zhangsheng Yu. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
Clinical journal of the American Society of Nephrology : CJASN.
2010 Feb; 5(2):299-306. doi:
10.2215/cjn.07131009. [PMID: 20056760] - Frank Gotch, Nathan W Levin, Peter Kotanko. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
Blood purification.
2010; 29(2):163-76. doi:
10.1159/000245924. [PMID: 20093823] - Yan Zhang, Dilip K Deb, Juan Kong, Gang Ning, Yurong Wang, George Li, Yunzi Chen, Zhongyi Zhang, Stephen Strugnell, Yves Sabbagh, Cynthia Arbeeny, Yan Chun Li. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
American journal of physiology. Renal physiology.
2009 Sep; 297(3):F791-801. doi:
10.1152/ajprenal.00247.2009. [PMID: 19535571] - Neil Kumar, Jill Lindberg, Kristin David, Jonathan Morris, José Menoyo. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
American journal of nephrology.
2009; 29(2):71-8. doi:
10.1159/000151275. [PMID: 18689981] - William Noonan, Kristin Koch, Masaki Nakane, Junli Ma, Doug Dixon, Antoinette Bolin, Glenn Reinhart. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2008 Dec; 23(12):3824-30. doi:
10.1093/ndt/gfn375. [PMID: 18644798] - E Gonzalez. Vitamin D receptor ligand therapy in chronic kidney disease.
Clinical nephrology.
2008 Oct; 70(4):271-83. doi:
NULL. [PMID: 18826852] - S Z Fadem, F Al-Saghir, G Zollner, S Swan. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.
Clinical nephrology.
2008 Oct; 70(4):319-24. doi:
10.5414/cnp70319. [PMID: 18826857] - Glenville Jones. Pharmacokinetics of vitamin D toxicity.
The American journal of clinical nutrition.
2008 Aug; 88(2):582S-586S. doi:
10.1093/ajcn/88.2.582s. [PMID: 18689406] - Steven Attia, Jens Eickhoff, George Wilding, Douglas McNeel, Jules Blank, Harish Ahuja, Alcee Jumonville, Michael Eastman, Daniel Shevrin, Michael Glode, Dona Alberti, Mary Jane Staab, Dottie Horvath, Jane Straus, Rebecca Marnocha, Glenn Liu. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2008 Apr; 14(8):2437-43. doi:
10.1158/1078-0432.ccr-07-4274. [PMID: 18413835] - Frank A Gesek, Jennifer S Desmond. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
Nephrology nursing journal : journal of the American Nephrology Nurses' Association.
2008 Mar; 35(2 Suppl):5S-22S; quiz 23S. doi:
NULL. [PMID: 18505229] - Dennis L Andress, Daniel W Coyne, Kamyar Kalantar-Zadeh, Mark E Molitch, Farhad Zangeneh, Stuart M Sprague. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
2008 Jan; 14(1):18-27. doi:
10.4158/ep.14.1.18. [PMID: 18238737] - Paul R van Ginkel, William Yang, Marcus M Marcet, Clement C Chow, Amol D Kulkarni, Soesiawati Darjatmoko, Mary J Lindstrom, Janice Lokken, Saswati Bhattacharya, Daniel M Albert. 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.
Journal of neuro-oncology.
2007 Dec; 85(3):255-62. doi:
10.1007/s11060-007-9418-z. [PMID: 17603751] - M Mizobuchi, J L Finch, D R Martin, E Slatopolsky. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
Kidney international.
2007 Sep; 72(6):709-15. doi:
10.1038/sj.ki.5002406. [PMID: 17597697] - Hiroshi Kaji. [Treatment of hypoparathyroidism by active vitamin D].
Clinical calcium.
2007 Aug; 17(8):1249-54. doi:
clica070812491254. [PMID: 17660623] - Melanie S Joy, Paul C Karagiannis, Fred W Peyerl. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Journal of managed care pharmacy : JMCP.
2007 Jun; 13(5):397-411. doi:
10.18553/jmcp.2007.13.5.397. [PMID: 17605511] - Takashi Akiba. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Clinical calcium.
2007 May; 17(5):767-71. doi:
clica0705767771. [PMID: 17471008] - K Kalantar-Zadeh. Survival differences between activated injectable vitamin D2 and D3 analogs.
Kidney international.
2007 Apr; 71(8):827; author reply 827-8. doi:
10.1038/sj.ki.5002208. [PMID: 17429422] - Diego Brancaccio, Jürgen Bommer, Daniel Coyne. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Drugs.
2007; 67(14):1981-98. doi:
10.2165/00003495-200767140-00002. [PMID: 17883283] - Dennis Andress. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Drugs.
2007; 67(14):1999-2012. doi:
10.2165/00003495-200767140-00003. [PMID: 17883284] - Vincent C Dennis, Guy L Albertson. Doxercalciferol treatment of secondary hyperparathyroidism.
The Annals of pharmacotherapy.
2006 Nov; 40(11):1955-65. doi:
10.1345/aph.1g523. [PMID: 17062838] - F Tentori, W C Hunt, C A Stidley, M R Rohrscheib, E J Bedrick, K B Meyer, H K Johnson, P G Zager. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Kidney international.
2006 Nov; 70(10):1858-65. doi:
10.1038/sj.ki.5001868. [PMID: 17021609] - H E Joist, S N Ahya, K Giles, K Norwood, E Slatopolsky, D W Coyne. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Clinical nephrology.
2006 May; 65(5):335-41. doi:
10.5414/cnp65335. [PMID: 16724654] - Glenn M Chertow, Samuel Blumenthal, Stewart Turner, Michael Roppolo, Leonard Stern, Eric M Chi, John Reed. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Clinical journal of the American Society of Nephrology : CJASN.
2006 Mar; 1(2):305-12. doi:
10.2215/cjn.00870805. [PMID: 17699221] - Anna L Zisman, Walid Ghantous, Pamela Schinleber, Laurie Roberts, Stuart M Sprague. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
American journal of nephrology.
2005 Nov; 25(6):591-5. doi:
10.1159/000089707. [PMID: 16282676] - Isidro B Salusky, William G Goodman, Shobha Sahney, Barbara Gales, Ashley Perilloux, He-Jing Wang, Robert M Elashoff, Harald Jüppner. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Journal of the American Society of Nephrology : JASN.
2005 Aug; 16(8):2501-8. doi:
10.1681/asn.2004100885. [PMID: 15944337] - Isidro B Salusky. Are new vitamin D analogues in renal bone disease superior to calcitriol?.
Pediatric nephrology (Berlin, Germany).
2005 Mar; 20(3):393-8. doi:
10.1007/s00467-004-1788-2. [PMID: 15690188] - Daniel M Albert, Amit Kumar, Stephen A Strugnell, Soesiawati R Darjatmoko, Janice M Lokken, Mary J Lindstrom, Sarit Patel. Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models.
Archives of ophthalmology (Chicago, Ill. : 1960).
2004 Sep; 122(9):1357-62. doi:
10.1001/archopht.122.9.1357. [PMID: 15364716] - Daniel M Albert, Amit Kumar, Stephen A Strugnell, Soesiawati R Darjatmoko, Janice M Lokken, Mary J Lindstrom, Christine M Damico, Sarit Patel. Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model.
Archives of ophthalmology (Chicago, Ill. : 1960).
2004 Sep; 122(9):1365-9. doi:
10.1001/archopht.122.9.1365. [PMID: 15364717] - Jack W Coburn, Hla M Maung, Logan Elangovan, Michael J Germain, Jill S Lindberg, Stuart M Sprague, Mark E Williams, Charles W Bishop. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2004 May; 43(5):877-90. doi:
10.1053/j.ajkd.2004.01.012. [PMID: 15112179] - Naoko Miwa, Takashi Akiba. [The trend in the development of the active vitamin D3 and its analogues].
Nihon rinsho. Japanese journal of clinical medicine.
2004 May; 62 Suppl 5(?):364-7. doi:
NULL. [PMID: 15197946] - Tilman B Drüeke. Calcimimetics versus vitamin D: what are their relative roles?.
Blood purification.
2004; 22(1):38-43. doi:
10.1159/000074922. [PMID: 14732810] - Drasko Pavlović, Hrvojka Tomić Brzac. Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist?.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Jul; 18 Suppl 5(?):v45-6. doi:
10.1093/ndt/gfg1045. [PMID: 12817069] - M S Parisi, B Oliveri, J Somoza, C Mautalen. Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy.
Clinical nephrology.
2003 Jun; 59(6):471-4. doi:
10.5414/cnp59471. [PMID: 12834181] - D Brancaccio, M Cozzolino, A Galassi, A Bellasi, P Carpani, M Gallieni. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2003 May; 20 Suppl 22(?):S12-6. doi:
NULL. [PMID: 12851915] - Daniel G Dawson, Joel Gleiser, Michele L Zimbric, Soesiawaiti R Darjatmoko, Mary J Lindstrom, Stephen A Strugnell, Daniel M Albert. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.
Ophthalmology.
2003 Apr; 110(4):835-9. doi:
10.1016/s0161-6420(02)01934-6. [PMID: 12689912] - Robert A Upton, Joyce C Knutson, Charles W Bishop, Leon W LeVan. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2003 Apr; 18(4):750-8. doi:
10.1093/ndt/gfg030. [PMID: 12637645] - Eduardo Slatopolsky, Mario Cozzolino, Jane L Finch. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.
Kidney international.
2002 Oct; 62(4):1277-84. doi:
10.1111/j.1523-1755.2002.kid573.x. [PMID: 12234297] - Glenn Liu, Kurt Oettel, Gregory Ripple, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Arzoomanian, Rebecca Marnocha, Reginald Bruskewitz, Richard Mazess, Charles Bishop, Abhik Bhattacharya, Howard Bailey, George Wilding. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Sep; 8(9):2820-7. doi:
. [PMID: 12231522] - George R Bailie, Curtis A Johnson. Comparative review of the pharmacokinetics of vitamin D analogues.
Seminars in dialysis.
2002 Sep; 15(5):352-7. doi:
10.1046/j.1525-139x.2002.00086.x. [PMID: 12358640] - Richard J Grostern, Paul J Bryar, Michele L Zimbric, Soesiawati R Darjatmoko, Boaz J Lissauer, Mary J Lindstrom, Janice M Lokken, Stephen A Strugnell, Daniel M Albert. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.
Archives of ophthalmology (Chicago, Ill. : 1960).
2002 May; 120(5):607-12. doi:
10.1001/archopht.120.5.607. [PMID: 12003610] - Daniel G Dawson, Joel Gleiser, Michele L Zimbric, Soesiawaiti R Darjatmoko, Jared C Frisbie, Janice M Lokken, Mary J Lindstrom, Isabelle Audo, Stephen A Strugnell, Daniel M Albert. Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.
Transactions of the American Ophthalmological Society.
2002; 100(?):125-9. doi:
NULL. [PMID: 12545685] - Alex J Brown, Adriana S Dusso, Eduardo Slatopolsky. Vitamin D analogues for secondary hyperparathyroidism.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2002; 17 Suppl 10(?):10-9. doi:
10.1093/ndt/17.suppl_10.10. [PMID: 12386264] - K J Martin, E A González. Vitamin D analogues for the management of secondary hyperparathyroidism.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2001 Nov; 38(5 Suppl 5):S34-40. doi:
10.1053/ajkd.2001.28109. [PMID: 11689385] - J S Lindberg. New vitamin D analogs.
Seminars in dialysis.
2001 May; 14(3):229-30. doi:
10.1046/j.1525-139x.2001.00057-3.x. [PMID: 11422933] - J L Goode. Bone disease: a primer/Part I. Clinical differences among vitamin D hormone compounds.
Nephrology news & issues.
2001 May; 15(6):22-3. doi:
NULL. [PMID: 12108997] - K Weber, M Goldberg, M Stangassinger, R G Erben. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2001 Apr; 16(4):639-51. doi:
10.1359/jbmr.2001.16.4.639. [PMID: 11315991] - H M Maung, L Elangovan, J M Frazão, J D Bower, B J Kelley, S R Acchiardo, H J Rodriguez, K C Norris, J F Sigala, M Rutkowski, J A Robertson, W G Goodman, B S Levine, R W Chesney, R B Mazess, D M Kyllo, L L Douglass, C W Bishop, J W Coburn. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2001 Mar; 37(3):532-43. doi:
10.1053/ajkd.2001.22077. [PMID: 11228177] - J M Frazão, L Elangovan, H M Maung, R W Chesney, S R Acchiardo, J D Bower, B J Kelley, H J Rodriguez, K C Norris, J A Robertson, B S Levine, W G Goodman, D Gentile, R B Mazess, D M Kyllo, L L Douglass, C W Bishop, J W Coburn. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2000 Sep; 36(3):550-61. doi:
10.1053/ajkd.2000.16193. [PMID: 10977787] - W L St Peter. Hectorol: a new vitamin D prohormone.
Nephrology nursing journal : journal of the American Nephrology Nurses' Association.
2000 Feb; 27(1):67-8. doi:
NULL. [PMID: 10852695] - NULL. New drug overview. Doxercalciferol.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
1999 Dec; 56(23):2410-1. doi:
10.1093/ajhp/56.23.2410. [PMID: 10595800] - J M Frazao, R W Chesney, J W Coburn. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
1998; 13 Suppl 3(?):68-72. doi:
10.1093/ndt/13.suppl_3.68. [PMID: 9568825] - R G Erben, U Bante, H Birner, M Stangassinger. 1alpha-hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats.
Calcified tissue international.
1997 May; 60(5):449-56. doi:
10.1007/s002239900261. [PMID: 9115163] - J W Coburn, A U Tan, B S Levine, R B Mazess, D M Kyllo, J C Knutson, C W Bishop. 1 alpha-Hydroxy-vitamin D2: a new look at an 'old' compound.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
1996; 11 Suppl 3(?):153-7. doi:
10.1093/ndt/11.supp3.153. [PMID: 8840332] - J C Knutson, B W Hollis, L W LeVan, C Valliere, K G Gould, C W Bishop. Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys.
Endocrinology.
1995 Nov; 136(11):4749-53. doi:
10.1210/endo.136.11.7588202. [PMID: 7588202] - J C Gallagher, C W Bishop, J C Knutson, R B Mazess, H F DeLuca. Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
1994 May; 9(5):607-14. doi:
10.1002/jbmr.5650090504. [PMID: 8053388] - A I Airede. Rickets of prematurity: a case report.
East African medical journal.
1991 Dec; 68(12):1006-14. doi:
NULL. [PMID: 1800088] - G Sjöden, C Smith, U Lindgren, H F DeLuca. 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
1985 Mar; 178(3):432-6. doi:
10.3181/00379727-178-42028. [PMID: 3871952] - G Sjödén. Effects of vitamin D. A comparison of 1 alpha OHD2 and 1 alpha OHD3 in rats.
Acta orthopaedica Scandinavica. Supplementum.
1985; 217(?):1-84. doi:
NULL. [PMID: 3911723] - G Sjöden, J U Lindgren, H F DeLuca. Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats.
The Journal of nutrition.
1984 Nov; 114(11):2043-6. doi:
10.1093/jn/114.11.2043. [PMID: 6333501] - G O Sjödén, O Johnell, H F DeLuca, J U Lindgren. Effects of 1 alpha OHD2 on bone tissue. Studies of 1 alpha OHD2 and 1 alpha OHD3 in normal rats and in rats treated with prednisolone.
Acta endocrinologica.
1984 Aug; 106(4):564-8. doi:
10.1530/acta.0.1060564. [PMID: 6332445]
